



## Europass Curriculum

### Personal information

First name / Surname **LAURA BALLOTTA**

Address Piazzale dell'Ospitale 1  
34125, Trieste

Telephone /

E-mail [laura.ballotta@asugi.sanita.fvg.it](mailto:laura.ballotta@asugi.sanita.fvg.it)

Nationality Italian

Medical licence Number 05566 Ordine dei Medici / Odontoiatri di Treviso

### Work experience

Dates **November 2020 – Ongoing**

Occupation or position held Research fellow affiliated with the Department of Medicine, Surgery and Health Sciences, University of Trieste

Main activities and responsibilities Clinical and research activity in haematology department, mainly focused on Lymphoproliferative Diseases

Name and address of employer SC Ematologia II piano, Ospedale Maggiore – Azienda Sanitaria Universitaria Giuliano Isontina, Piazza dell'Ospitale 1,  
34125 Trieste Italy

Type of business or sector Health Service

Dates **November 2016 – October 2020**

Occupation or position held Specializing Doctor

Main activities and responsibilities Clinical activity in the Hematology Department and Research activity on Lymphoproliferative Diseases, Immunohematology and Trasfusion Medicine, Autologous Stem Cell Transplantation, Acute Myeloid and Lymphoid Leukemia, Myeloproliferative Neoplasms, Emostasis and Thrombosis.

Name and address of employer Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome  
Via Benevento 6  
000161, Rome

Type of business or sector	Health Service
<b>Education and training</b>	
Dates	<b>November 2016 – October 2020</b>
Title of qualification awarded	Specialization in Hematology
Principal subjects/occupational skills covered	Hematological Diseases (Clinical and Research activity), mainly focused on Lymphoproliferative Diseases, Immunohematology and Trasfusion Medicine, Autologous Stem Cell Transplantation, Acute Myeloid and Lymphoid Leukemia, Myeloproliferative Neoplasms, Emostasis and Thrombosis.  Thesis title: "Role of immunotherapy in relapsed/refractory Hodgkin Lymphoma patients treated with ASCT"
Name and type of organization providing education and training	Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome Via Benevento 6 000161, Rome
Level in national or international classification	70/70 & lode
Dates	<b>April 2016- June 2016</b>
Title of qualification awarded	Authorization to practice (state examination)
Principal subjects/occupational skills covered	Practice training in Surgery, Internal Medicine Department and GP Ambulatory
Name and type of organization providing education and training	University of Ferrara, Italy
Level in national or international classification	Enabled
Dates	<b>October 2008 - March 2016</b>
Title of qualification awarded	Master Degree in Medicine and Surgery

Principal subjects/occupational skills covered	General Medicine and Surgery (theory and practice). Internship in Neonatal Intensive Care. Thesis title: "Role of vaccination in premature newborns"				
Name and type of organization providing education and training	University of Ferrara, Italy				
Level in national or international classification	110/110 & lode				
Dates	<b>September 2002 - June 2007</b>				
Title of qualification awarded	High School Diploma				
Principal subjects/occupational skills covered	Scientific High School				
Name and type of organization providing education and training	"Collegio Immacolata" scientific High School via Madonna 20, 31015 Conegliano (TV) Italy				
Level in national or international classification	92/100				
<b>Personal skills and competences</b>	Excellent skills in individual and team working. Excellent skills in organizing work project. Excellent skills in communication with colleagues and patients				
Mother tongue(s)	<b>Italian</b>				
Other language(s)	<b>English; French</b>				
Self-assessment	<b>Understanding</b>		<b>Speaking</b>		<b>Writing</b>
<i>European level (*)</i>	Listening	Reading	Spoken interaction	Spoken production	
<b>English</b>	B2	B2	B2	B2	B2
<b>French</b>	A2	A2	A2	A2	A2
	(*) <a href="#">Common European Framework of Reference for Languages</a>				
Computer skills and competences	Basic knowledge of Windows environment (word processing, spreadsheet and graphics processing, internet, power-point presentations)				
Driving license	B				
<b>Editorial Activities</b>	1) Pulsoni A, Cappelli LV, <b>Ballotta L</b> , Canichella M, Serrao A, Annechini G, D'Elia GM, Foà R. Current and future therapeutic approaches for the treatment of follicular lymphoma. Expert Rev Anticancer Ther. 2018 Sep;18(9):931-941. doi: 10.1080/14737140.2018.1493926. Epub 2018 Jul 16. PMID: 29972084. 2) Marchesi F, Capria S, Pedata M, Terrenato I, <b>Ballotta L</b> , Riccardi C, Papa E, Riemma C, Trisolini S, Celentano M, Regazzo G, Ferrara F, Mengarelli A, Picardi A. BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant. Leuk Lymphoma. 2020 Sep;61(9):2238-2241. doi: 10.1080/10428194.2020.1765238. Epub 2020 May 18. PMID: 32419550.				

- 3) **Ballotta L**, Trisolini SM, Iori AP, La Rocca U, Micozzi A, Gentile G, De Giacomo T, Guarini A, Foà R, Capria S. A Rare Case of Coexisting Breast Cancer and Refractory Acute Myeloid Leukemia. *Case Rep Hematol.* 2020 Aug 25;2020:8893185. doi: 10.1155/2020/8893185. PMID: 32908731; PMCID: PMC7468610.
- 4) Serrao A, **Ballotta L**, Dragoni F, Pallotta A, Chistolini A. Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia. *Thromb Res.* 2020 Dec;196:539-540. doi: 10.1016/j.thromres.2020.10.020. Epub 2020 Oct 20. PMID: 33126052.
- 5) Lucchini E, Merlo M, Ballerini M, Porcari A, Sinagra G, Pagnan L, Rensi M, Romano A, Bussani R, **Ballotta L**, Zaja F. Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors. *Front Oncol.* 2021 Apr 27;11:665736. doi: 10.3389/fonc.2021.665736. PMID: 33987101; PMCID: PMC8112198.
- 6) Bega G, Olivieri J, Riva M, Scapinello G, Paolini R, Finotto S, Sartori R, Lucchini E, Guandalini G, Facchinelli D, Tisi MC, Basso M, **Ballotta L**, Piazza F, Ferrarini I, Visco C. Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma. *Cancers (Basel).* 2021 Dec 3;13(23):6089. doi: 10.3390/cancers13236089. PMID: 34885198; PMCID: PMC8657015.
- 7) **Ballotta L**, Zinzani PL, Pileri S, Bruna R, Tani M, Casadei B, Tabanelli V, Volpetti S, Luminari S, Corradini P, Lucchini E, Tisi MC, Merli M, Re A, Varettoni M, Pesce EA, Zaja F. Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi. *Front Oncol.* 2021 Dec 6;11:789891. doi: 10.3389/fonc.2021.789891. PMID: 34938664; PMCID: PMC8685372.
- 8) **Ballotta L**, Simonetti O, D'Agaro P, Segat L, Koncan R, Martinez-Orellana P, Dattola F, Orsini E, Marcello A, Dal Monego S, Licastro D, Misin A, Mohamed S, Sbisà E, Lucchini E, De Sabbata GM, Zaja F, Luzzati R. Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab. *Front Oncol.* 2022 Sep 30;12:945060. doi: 10.3389/fonc.2022.945060. PMID: 36249044; PMCID: PMC9561900.
- 9) **Ballotta L**, Maccaferri M, De Paoli L, Orsucci L, Gottardi D, Chiurazzi F, Reda G, Moia R, Cuneo A, Foà R, Marasca R. Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report. *Hematol Oncol.* 2023 Feb;41(1):201-204. doi: 10.1002/hon.3047. Epub 2022 Aug 19. PMID: 35849302.
- 10) Mohamed S, Lucchini E, Sirianni F, Porrizzo M, **Ballotta L**, Ballerini M, De Sabbata GM, De Bellis E, Cappuccio I, Granzotto M, Toffoletto B, Fortunati I, Russignan A, Florea EE, Torelli L, Zaja F. Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study "Cervax". *Front Oncol.* 2023 Feb 27;13:1133348. doi: 10.3389/fonc.2023.1133348. PMID: 36923438; PMCID: PMC10008958.

#### **ABSTRACT presentation during EHA 2021**

- 1) Bega G, Riva M, Scapinello G, Finotto S, Sartori R, Lucchini E, Olivieri J, Guandalini G, Facchinelli D, Tisi MC, Basso M, **Ballotta L**, Piazza F, Ferrarini I, Visco C. Rituximab, Bendamustine and Cytarabine (R-BAC) compared with

	<p>Rituximab and Bendamustine (BR) in previously untreated elderly patients with mantle cell lymphoma (BE-VE-BAC study). 325553; EP795</p> <p>2) Zaja F, Zinzani PL, Varettoni M, <b>Ballotta L</b>, Lucchini E, Pellegrini C, Gaidano G, Bruna R, Tani M, Volpetti S, Luminari S, Corradini P, Tisi MC, Merli M, Re A, Marcheselli R, Pesce EA, Pileri S. Venetoclax as single agent in BCL2-positive relapsed/refractory peripheral T-cell lymphomas. A phase 2 study of the Fondazione Italiana Linfomi. 325303; EP543</p> <p><b>ABSTRACT presentation during EHA 2022</b></p> <p>Bomben R, Rossi FM, Vit F, Bittolo T, Zucchetto A, Papotti R, Tissino E, Pozzo F, Degan M, Zaina E, Cattarossi I, Nanni P, Marasca R, Reda G, Laurenti L, Olivieri J, Chiarenza A, <b>Ballotta L</b>, Cuneo A, Gentile M, Morabito F, Tafuri A, Zaja F, Foà R, Di Raimondo F, Del Poeta G, Gattei V. P596 CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE</p> <p><b>ABSTRACT and poster presentation during SIE 2022</b></p> <p>Bomben R, Rossi FM, Vit F, Bittolo T, Zucchetto A, Papotti R, Tissino E, Pozzo F, Degan M, Zaina E, Cattarossi I, Nanni P, Marasca R, Reda G, Laurenti L, Olivieri J, Chiarenza A, <b>Ballotta L</b>, Cuneo A, Gentile M, Morabito F, Tafuri A, Zaja F, Foà R, Di Raimondo F, Del Poeta G, Gattei V. C091 CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE</p> <p>S. Mohamed, E. Lucchini, F. Sirianni, M. Porrizzo, <b>L. Ballotta</b>, M. Ballerini, G.M. De Sabbata, E. De Bellis, I. Cappuccio, M. Granzotto, B. Toffoletto, M. Ruscio, A. Russignan, M. Krampera, L. Torelli, F. Zaja P013 SEROLOGICAL RESPONSE TO SARS-COV2-19 VACCINE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: RESULTS OF THE STUDY “CERVAX”</p> <p><b>L. Ballotta</b>, O. Simonetti, P. D’Agaro, L. Segat, R. Koncan, P.M. Orellana, F. Dattola, E. Orsini, A. Marcello, S. Dal Monego, D. Licastro, A. Misin, S. Mohamed, E. Sbisà, E. Lucchini, G.M. De Sabbata, R. Luzzati, F. Zaja P034 LONG LASTING SARS-COV2 INFECTION WITH POST-COVID-19 SYNDROME IN TWO PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EMERGING THERAPEUTIC ROLE OF CASIRIVIMAB/IMDEVIMAB</p> <p><b>ABSTRACT and poster presentation during SIE 2023</b></p> <p>E. Lucchini, A. Roncoli, I. Gandin, G. Russo, E. Sbisà, M. Ballerini, L. Ballotta, M.C. Rossetti, F. Zaja P031 REAL-LIFE ELDERLY PROGNOSTIC INDEX USEFULNESS FOR GUIDING TREATMENT CHOICES IN ELDERLY DLBCL PATIENTS</p> <p><b>Others:</b> co-PI in the PRIN project 20227RLEL8 - Myelodysplasia-related molecular abnormalities and Clonal Hematopoiesis in patients with relapsed-refractory lymphoid malignancies receiving chimeric antigen receptor (CAR) T Cells.</p>

In compliance with the Italian legislative Decree no. 193/2003 and art. 13 GDPR 679/16, I hereby authorize you to use and process my personal details contained in this document.

Date, 02/11/2023

Signature



